<DOC>
	<DOCNO>NCT00391690</DOCNO>
	<brief_summary>It aim prospective , single-group , clinical study ass whether bone parameter use diagnostic tool early detection bone metastases patient high risk prostate cancer . The usefulness monitoring zoledronic acid therapy patient develop bone metastasis also assess .</brief_summary>
	<brief_title>Evaluation Bone Markers Diagnostic Tools Early Detection Bone Metastases Patients With High Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Inclusion criterion : Patients histologically confirm diagnosis prostate cancer yet develop bone metastasis Prostate cancer patient rise PSA hormone therapy . PSA criterion : Patients undergone prostatectomy : rise PSA Patients without prostatectomy : 2 consecutive rise PSA level relative previous reference value , separate one month . The first measurement must occur one month reference value must reference value . The second confirmatory measurement take one month first measurement must great first measurement . Previous chemotherapy radiotherapy must perform ≥ 8 week prior study entry . Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 ( patient spend less 50 % time bed day ) Adequate liver function serum total bilirubin concentration le 1.5 x upper limit normal value Age : ≥ 18 year Patient give write informed consent prior studyspecific procedure . Patients psychiatric addictive disorder prevent give informed consent must enter study . Exclusion criterion : Prior treatment bisphosphonate Abnormal renal function evidence calculated creatinine clearance &lt; 30 ml/minute . Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) ≥ 12.0 mg/dl ( 3.00 mmol/L ) . Patients clinically symptomatic brain metastasis History diseases influence bone metabolism Paget 's disease primary hyperparathyroidism Severe physical psychological concomitant disease might impair compliance provision study protocol might impair assessment drug patient safety , e.g . clinically significant ascites , cardiac failure , NYHA III IV , clinically relevant pathologic finding ECG Known hypersensitivity zoledronic acid bisphosphonates Use investigational drug 30 day prior date randomization Known history present abuse alcohol drug Subjects , opinion investigator , unlikely cooperate fully study Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Serum bone marker</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Bisphosphonates</keyword>
	<keyword>Early detection metastasis</keyword>
</DOC>